Background: Hidradenitis suppurativa (HS) is a chronic inflammatory relapsing disease involving the axillae, breast ,groin and anogenital regions. The therapies of the disease are diverse, including medication and surgery. However, responses to treatments are variable and relapse is common, with no single agent being consistently effective. Objective: To evaluate the efficacy and safety of oral mesalazine treatment for hidradenitis suppurativa . Methods: Investigators reported a series of cases of patients who received oral mesalazine(1g qid) for hidradenitis suppurativa in our institution between May 2020 and September 2023. A total of 27 patients, 22 in the mild to moderate group and 5 in the severe group, were included in this study.
Study Type
OBSERVATIONAL
Enrollment
27
oral mesalazine 1g qid
Jiangsu Provincial People's Hospital
Nanjing, Nanjing, China
Therapeutic Effect of Methalazine on 27 Cases of Suppurative Hidradenitis
We registered the number of patients who achieved HiSCR(%).
Time frame: Three and a half years
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.